SEATTLE, May 10, 2010 /PRNewswire via COMTEX/ -- Oncothyreon Inc. (NASDAQ: ONTY) today announced that it received written confirmation on May 7, 2010 from the Nasdaq Listing Qualifications Staff that the company has demonstrated compliance with Nasdaq Marketplace Rule 5250(c)(1) for continued listing of the company's securities on The Nasdaq Stock Market. The compliance notification from Nasdaq follows the filing of the company's Annual Report on Form 10-K for the fiscal year ended December 30, 2009 with the Securities and Exchange Commission on May 6, 2010.
About Oncothyreon Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer. Oncothyreon's goal is to develop and commercialize novel synthetic vaccines and targeted small molecules that have the potential to improve the lives and outcomes of cancer patients. For more information, visit www.oncothyreon.com.
Additional Information Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on SEDAR at www.sedar.com.
SOURCE Oncothyreon Inc.
www.prnewswire.com Copyright (C) 2010 PR Newswire. All rights reserved -0- KEYWORD: Washington